Table 2.
Characteristics of patients at presentation with exacerbation with rhinovirus or other viruses at exacerbation.
| Rhinovirus (n=34) |
Other viruses (n=10) |
p-value | |
|---|---|---|---|
| Gender (% females) | 68 | 70 | 0.89 |
| Age | 29 (9) | 41 (17) | 0.06 |
| Smokers (% never; former; current) | 65; 15; 20 | 60; 30; 10 | 0.47 |
| Packyears (among former and current smokers) | 6.0 (5.4) | 1.7 (1.6) | 0.15 |
| Atopic (%) | 62 | 40 | 0.22 |
| ICS dose (daily budesonide eq.) | 200 (0–2400) | 800 (0–800) | 0.34 |
| ACQ | 3.4 (1.4) | 2.3 (1.4) | 0.03 |
| FEV1 %pred. | 77.2 (16.0) | 90.8 (15.5) | 0.02 |
| FVC %pred. | 87.1 (14.4) | 94.9 (11.8) | 0.13 |
| Beta-2-agonist within 8 hours? (%) | 46 | 25 | 0.29 |
| FeNO (ppb)a | 29 (23–37) | 24 (15–38) | 0.41 |
| Blood eosinophils (×109 cells/L) | 0.07 (0–1.32) | 0.13 (0–0.41) | 0.84 |
| Blood neutrophils (×109 cells/L) | 6.2 (2.1–14.1) | 3.6 (2.9–10.2) | 0.13 |
| Total IgE (×103 IU/L)a | 167 (85–328) | 96 (31–298) | 0.41 |
| CRP (mg/L)a | 8.5 (6.0–12.0) | 8.2 (3.5–19.1) | 0.93 |
| n=27 | n=9 | ||
|
|
|||
| Sputum total cell count (×106/ml) a | 1.0 (0.6–1.7) | 2.2 (0.9–5.4) | 0.11 |
| Sputum eosinophils (×106/ml) a | 0.07 (0.04–0.13) | 0.06 (0.02–0.16) | 0.80 |
| Sputum %-eosinophils a | 1.2 (0.5–3.0) | 0.9 (0.3–3.2) | 0.75 |
| Sputum neutrophils (×106/ml) a | 0.5 (0.2–0.9) | 1.1 (0.3–3.8) | 0.20 |
| Sputum %-neutrophils a | 45.9 (32.0–66.0) | 51.3 (28.3–93.0) | 0.75 |
a
Log-transformed and presented as geometric mean (95% CI).